William Messer
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Background The yellow fever vaccine 17D has controlled yellow fever for almost 90 years and is considered highly successful. However, with recent outbreaks in South America and Africa, yellow fever continues to represent a significant threat to public and global health. Despite its longstanding success, few studies have characterized the capacity of 17D-immune sera to neutralize wild-type (WT) yellow fever viruses (YFVs). Methods We use 17D and a panel of 13 WT YFVs that represent the known YFV genotypes and a unique cohort of 36 non-endemic vaccinees with diverse Orthoflavivirus infection histories to conduct focus neutralization tests to characterized the potency and breadth of 17D-elicited serum neutralizing antibodies against these WT YFV. Results We found significant variability in neutralization test titers and rates of seropositivity of 17D-immune sera across all viruses and specifically against South America-genotype I (SA-I) isolates. Vaccinee sera with serologic evidence of heterologous Orthoflavivirus infection had significantly greater potency against SA-I strains compared to sera without evidence of Orthoflavivirus infection, suggesting a boosting effect from heterologous Orthoflavivirus immunity. Conclusions These results add significantly to what is known regarding the WT YFV antigenic immune landscape, including novel insights into the role of heterologous Orthoflavivirus infection in 17D immunity that have the potential to improve future vaccine design and deployment strategies.
Year:
2026
The yellow fever vaccine 17D has controlled yellow fever for almost 90 years and is considered highly successful. However, with recent outbreaks in South America and Africa, yellow fever continues to represent a significant threat to public and global health. Despite its longstanding success, few studies have characterized the capacity of 17D-immune sera to neutralize wild-type (WT) yellow fever viruses (YFVs). Using a panel of WT YFVs that represent the known YFV genotypes and a unique cohort of non-endemic vaccinees with diverse Orthoflavivirus infection histories, we extensively characterized the potency and breadth of 17D-elicited serum neutralizing antibodies against these WT YFV. We found significant variability in neutralization test (NT) titers and rates of seropositivity of 17D-immune sera against South America-genotype I (SA-I) isolates. Vaccinee sera with serologic evidence of heterologous Orthoflavivirus infection had significantly great potency against SA-I strains compared to sera without evidence of Orthoflavivirus infection, suggesting a boosting effect from heterologous Orthoflavivirus immunity. These results add significantly to what is known regarding WT YFV antigenic immune landscape, including novel insights into the role of heterologous Orthoflavivirus infection in 17D immunity that have the potential to improve future vaccine strategies.
Year:
2025
Year:
2024
Hospitalized COVID-19 patients exhibit diverse immune responses during acute infection, which are associated with a wide range of clinical outcomes. However, understanding these immune heterogeneities and their links to various clinical complications, especially long COVID, remains a challenge. In this study, we performed unsupervised subtyping of longitudinal multi-omics immunophenotyping in over 1,000 hospitalized patients, identifying two critical subtypes linked to mortality or mechanical ventilation with prolonged hospital stay and three severe subtypes associated with timely acute recovery. We confirmed that unresolved systemic inflammation and T-cell dysfunctions were hallmarks of increased severity and further distinguished patients with similar acute respiratory severity by their distinct immune profiles, which correlated with differences in demographic and clinical complications. Notably, one critical subtype (SubF) was uniquely characterized by early excessive inflammation, insufficient anticoagulation, and fatty acid dysregulation, alongside higher incidences of hematologic, cardiac, and renal complications, and an elevated risk of long COVID. Among the severe subtypes, significant differences in viral clearance and early antiviral responses were observed, with one subtype (SubC) showing strong early T-cell cytotoxicity but a poor humoral response, slower viral clearance, and greater risks of chronic organ dysfunction and long COVID. These findings provide crucial insights into the complex and context-dependent nature of COVID-19 immune responses, highlighting the importance of personalized therapeutic strategies to improve both acute and long-term outcomes.
Year:
2024
Year:
2023
Year:
2023
Collaborators (15)
Hanno Steen
Professor
Harvard Medical School
PENGHUA WANG
Associate Professor w/tenure
University of Connecticut Health Center
Joann Diray Arce
Assistant Professor
Boston Children's Hospital
Akiko Iwasaki
Professor
Yale University School of Medicine
Fikadu Tafesse
Professor and Chair
Oregon Health & Science University
Dina Fonseca
Professor, Department Chair
Rutgers University
Michael Wilson
Professor
University of California, San Francisco
Cole Maguire
University of Texas at Austin
Harm van Bakel
Associate Professor
Icahn School of Medicine at Mount Sinai
Al Ozonoff
Associate Professor
Harvard University
Harlan Krumholz
Professor of Medicine
Yale University
Savannah McBride
Columbia University
Lauren Ehrlich
Professor
University of Texas at Austin
Esther Annan
Cornell University
Juergen Pilz
Head of Department/ University Professor
Alpen-Adria-Universität Klagenfurt
Make your next move.
Prepare your application
Review drafts before you send them.